A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

This pilot study is testing a maintenance therapy regimen — using two drugs (decitabine and filgrastim) — given after a bone marrow transplant to prevent leukemia or related blood cancers from returning in children and young adults. **You may be eligible if...** - You have a confirmed diagnosis of AML (acute myeloid leukemia), MDS (myelodysplastic syndrome), or a related blood cancer - You have recently undergone a bone marrow (hematopoietic stem cell) transplant - Other disease-specific and post-transplant eligibility criteria apply **You may NOT be eligible if...** - Your cancer diagnosis does not match the specified types - You have not yet had a bone marrow transplant - Other health conditions or timing criteria apply Talk to your doctor to see if this trial is right for you.